FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025834385> ?p ?o ?g. }

• W2025834385 endingPage "1968" @default.
• W2025834385 startingPage "1965" @default.
• W2025834385 abstract "Background. 5-Fluorouracil (5-FU) has been previously associated with therapeutic benefit in hormone refractory prostate cancer. However, no previous study has administered 5-FU as a prolonged continuous infusion, which may be the optimal schedule for this cell-cycle specific agent. Methods. Therefore, 25 patients were treated with 5-FU administered as a continuous intravenous infusion at a dose of 1000 mg/m2/day for 5 days every 28 days. Eligibility required disease defined by bidimensionally measurable lesions or evaluable lesions on bone scan or radiograph with elevated serum levels of prostate-specific antigen (PSA), no severe cytopenias, and an Eastern Cooperative Oncology Group performance status less than 3. Prior chemotherapy was not allowed. Dose modifications were specified for mucositis and hematologic toxicity. Results. Eighteen of 22 patients were evaluable for response and toxicity, whereas 4 were evaluable for toxicity alone. Toxicity was significant using this dose and schedule and included episodes of sudden death (one patient), paroxysmal supraventricular tachycardia (one patient), and congestive heart failure (one patient). Other Grade 3 toxicities included stomatitis (two patients) and diarrhea (one patient). Significant myelosuppression did not occur. Objective responses were not observed, but 12 patients experienced stable disease with a median duration of 4 months. Conclusions. Infusional 5-FU can not be recommended for the treatment of advanced hormone refractory prostate cancer." @default.
• W2025834385 created "2016-06-24" @default.
• W2025834385 creator A5001124933 @default.
• W2025834385 creator A5003177689 @default.
• W2025834385 creator A5007395720 @default.
• W2025834385 creator A5013993910 @default.
• W2025834385 creator A5019669673 @default.
• W2025834385 creator A5025597179 @default.
• W2025834385 creator A5029706633 @default.
• W2025834385 creator A5059219836 @default.
• W2025834385 creator A5079124636 @default.
• W2025834385 creator A5083824775 @default.
• W2025834385 date "1993-09-15" @default.
• W2025834385 modified "2023-10-18" @default.
• W2025834385 title "A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study" @default.
• W2025834385 cites W1885154202 @default.
• W2025834385 cites W1902766545 @default.
• W2025834385 cites W1914185061 @default.
• W2025834385 cites W1964044815 @default.
• W2025834385 cites W2003374169 @default.
• W2025834385 cites W2025834385 @default.
• W2025834385 cites W2025865627 @default.
• W2025834385 cites W2035319437 @default.
• W2025834385 cites W2038273761 @default.
• W2025834385 cites W2055983050 @default.
• W2025834385 cites W2068334016 @default.
• W2025834385 cites W2094656553 @default.
• W2025834385 cites W2177330869 @default.
• W2025834385 cites W2204115562 @default.
• W2025834385 cites W2284629536 @default.
• W2025834385 cites W27570217 @default.
• W2025834385 cites W95164580 @default.
• W2025834385 doi "https://doi.org/10.1002/1097-0142(19930915)72:6<1965::aid-cncr2820720629>3.0.co;2-x" @default.
• W2025834385 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8364875" @default.
• W2025834385 hasPublicationYear "1993" @default.
• W2025834385 type Work @default.
• W2025834385 sameAs 2025834385 @default.
• W2025834385 citedByCount "25" @default.
• W2025834385 countsByYear W20258343852013 @default.
• W2025834385 countsByYear W20258343852017 @default.
• W2025834385 countsByYear W20258343852023 @default.
• W2025834385 crossrefType "journal-article" @default.
• W2025834385 hasAuthorship W2025834385A5001124933 @default.
• W2025834385 hasAuthorship W2025834385A5003177689 @default.
• W2025834385 hasAuthorship W2025834385A5007395720 @default.
• W2025834385 hasAuthorship W2025834385A5013993910 @default.
• W2025834385 hasAuthorship W2025834385A5019669673 @default.
• W2025834385 hasAuthorship W2025834385A5025597179 @default.
• W2025834385 hasAuthorship W2025834385A5029706633 @default.
• W2025834385 hasAuthorship W2025834385A5059219836 @default.
• W2025834385 hasAuthorship W2025834385A5079124636 @default.
• W2025834385 hasAuthorship W2025834385A5083824775 @default.
• W2025834385 hasBestOaLocation W20258343851 @default.
• W2025834385 hasConcept C121332964 @default.
• W2025834385 hasConcept C121608353 @default.
• W2025834385 hasConcept C126322002 @default.
• W2025834385 hasConcept C141071460 @default.
• W2025834385 hasConcept C142424586 @default.
• W2025834385 hasConcept C2776694085 @default.
• W2025834385 hasConcept C2778496288 @default.
• W2025834385 hasConcept C2778822529 @default.
• W2025834385 hasConcept C2779051857 @default.
• W2025834385 hasConcept C2780192828 @default.
• W2025834385 hasConcept C2780456651 @default.
• W2025834385 hasConcept C29730261 @default.
• W2025834385 hasConcept C71924100 @default.
• W2025834385 hasConcept C87355193 @default.
• W2025834385 hasConcept C90924648 @default.
• W2025834385 hasConceptScore W2025834385C121332964 @default.
• W2025834385 hasConceptScore W2025834385C121608353 @default.
• W2025834385 hasConceptScore W2025834385C126322002 @default.
• W2025834385 hasConceptScore W2025834385C141071460 @default.
• W2025834385 hasConceptScore W2025834385C142424586 @default.
• W2025834385 hasConceptScore W2025834385C2776694085 @default.
• W2025834385 hasConceptScore W2025834385C2778496288 @default.
• W2025834385 hasConceptScore W2025834385C2778822529 @default.
• W2025834385 hasConceptScore W2025834385C2779051857 @default.
• W2025834385 hasConceptScore W2025834385C2780192828 @default.
• W2025834385 hasConceptScore W2025834385C2780456651 @default.
• W2025834385 hasConceptScore W2025834385C29730261 @default.
• W2025834385 hasConceptScore W2025834385C71924100 @default.
• W2025834385 hasConceptScore W2025834385C87355193 @default.
• W2025834385 hasConceptScore W2025834385C90924648 @default.
• W2025834385 hasIssue "6" @default.
• W2025834385 hasLocation W20258343851 @default.
• W2025834385 hasLocation W20258343852 @default.
• W2025834385 hasOpenAccess W2025834385 @default.
• W2025834385 hasPrimaryLocation W20258343851 @default.
• W2025834385 hasRelatedWork W1583645249 @default.
• W2025834385 hasRelatedWork W1599611266 @default.
• W2025834385 hasRelatedWork W205106562 @default.
• W2025834385 hasRelatedWork W2164712168 @default.
• W2025834385 hasRelatedWork W2407004036 @default.
• W2025834385 hasRelatedWork W2563680907 @default.
• W2025834385 hasRelatedWork W2791355669 @default.
• W2025834385 hasRelatedWork W2960952620 @default.
• W2025834385 hasRelatedWork W3031142008 @default.
• W2025834385 hasRelatedWork W4226402975 @default.

• next